Objective: The aim of the study was the evaluation of risperidone effect on metabolite measures in the frontal lobe, temporal lobe and thalamus in schizophrenic patients on the basis of proton magnetic resonance spectroscopy (1 H MRS). Methods: A group of 14 patients with the diagnosis of schizophrenia, according to DSM-IV, were examined in the study. The patients were examined twice, once after a period of at least 7 days without neuroleptics and for the second time at least 4 weeks after stable risperidone doses. Results: The significant differences in the metabolite levels before and after the treatment were observed only in thalamus: an increase in myoinositol (mI) and N-acetylaspartate (NAA) levels. Positive symptoms before the treatment correlated positively with NAA level in the frontal lobes and negatively in the temporal lobes. Negative symptoms before the treatment correlated positively with Glx (a common signal for GABA, glutamine and glutamate) level in the temporal lobes. Conclusion: Our results seem to confirm the influence of risperidone on the brain metabolism, specifically in the region of thalamus.
References
1 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, International Version. Washington, DC; American Psychiatric Association 1995
2
Andreasen N C, Paradiso S, O’Leary D S.
”Cognitive dysmetria” as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?.
Schizophr Bull.
1998;
24
203-218
3
Bartha R, Al-Semaan Y M, Williamson P C, Drost D J, Malla A K, Carr T J. et al .
A short proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients.
Biol Psychiatry.
1999;
45
1403-1411
4
Bartha R, Williamson P C, Drost D J, Malla A, Carr T J, Cortese L. et al .
Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy.
Arch Gen Psychiatry.
1997;
54
959-965
5
Berger G E, Wood S J, Wellard M, Proffitt M T, McConchie M, Pantelis C. et al .
In vivo brain imaging and implications for neuroprotection in early psychosis.
World J Biol Psychiatry.
2004;
5 (Suppl 1)
20
6
Bertolino A, Callicott J H, Mattay V S, Weidenhammer K M, Rakow R, Egan M F. et al .
The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia.
Biol Psychiatry.
2001;
49
39-46
7
Bertolino A, Esposito G, Callicott J H, Mattay V S, Van Horn J D, Frank J A. et al .
Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia.
Am J Psychiatry.
2000;
157
26-33
8
Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A. et al .
Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder.
Am J Psychiatry.
2003;
160
483-489
9
Bustillo J R, Lauriello J, Rowland L M, Thomson L M, Petropoulos H, Hammond R. et al .
Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure.
Schizophr Res.
2002;
58
313-321
10
Bustillo J, Wolff C, Myers-y-Guterrez A, Dettmer T S, Cooper T B, Allan A. et al .
Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetylaspartate levels.
Schizophr Res.
2004;
66
31-39
11
Callicott J H, Bertolino A, Egan M F, Mattay V S, Langheim F JP, Weinberger D R.
Selective relationship between prefrontal N-acetylaspartate measures and negative smptoms in schizophrenia.
Am J Psychiatry.
2000;
157
1646-1651
12
Cecil K M, Lenkinski R E, Gur R E, Gur R C.
Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia.
Neuropsychopharmacology.
1999;
20
131-140
13
Choe B -Y, Suh T -S, Shinn K -S, Lee C -W, Lee C, Paik I -H.
Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy.
Invest Radiol.
1996;
31
345-352
14
Deicken R F, Johnson C, Eliaz Y, Schuff N.
Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia.
Am J Psychiatry.
2000;
157
644-647
15
Deicken R F, Zhou L, Corwin F, Vinogradov S, Weiner M W.
Decreased left frontal lobe N-acetylaspartate in schizophrenia.
Am J Psychiatry.
1997;
154
688-690
16
Deicken R F, Zhou L, Schuff N, Fein G, Weiner M W.
Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy.
Biol Psychiatry.
1998;
43
483-488
17
Delamillieure P, Fernandez J, Constans J -M, Brazo P, Benali K, Abadie P. et al .
Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report.
Am J Psychiatry.
2000;
157
641-643
18
Ende G, Braus D F, Walter S, Weber-Fahr W, Henn F A.
Multiregional 1 H-MRSI of the hippocampus, thalamus, and basal ganglia in schizophrenia.
Eur Arch Psychiatry Clin Neurosci.
2003;
253
9-15
19
Fannon D, Simmons A, Tennakoon L, O’Céallaigh S, Sumich A, Doku V. et al .
Selective deficit of hippocampal N-acetyaspartate in antipsychotic-naive patients with schizophrenia.
Biol Psychiatry.
2003;
54
587-598
20
Fukuzako H, Kodama S, Fukuzako T, Yamada K, Doi W, Sato D. et al .
Subtype-associated metabolite differences in the temporal lobe in schizophrenia detected by proton magnetic resonance spectroscopy.
Psychiatry Res Neuroimaging.
1999;
92
45-56
21
Goff D C, Hennen J, Lyoo I K, Tsai G, Wald L L, Evins A E. et al .
Modulation of Brain and serum Glutamatergic concentrations Following a switch from Conventional Neuroleptics to Olanzapine.
Biol Psychiatry.
2002;
51
493-497
22
Heimberg C, Komoroski R A, Lawson W B, Cardwell D, Karson C E.
Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect.
Psychiatry Res Neuroimaging.
1998;
83
105-115
23
Jones R S, Waldman A D.
1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia.
Neurol Res.
2004;
26
488-495
24
Kay S R, Fiszbein A, Opler L A.
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia.
Schizophr Bull.
1987;
13
261-276
25
Kantarci K, Petersen R C, Boeve B F, Knopman D S, Tang-Wai D F, O’Brien P C. et al .
1H MRS spectroscopy in common dementias.
Neurology.
2004;
63
1393-1398
26
Keshavan M S, Stanley J A, Pettegrew J W.
Magnetic Resonance Spectroscopy in Schizophrenia: Methodological Issues and Findings-Part II.
Biol Psychiatry.
2000;
48
369-80
27
Miyaoka T, Yasukawa R, Mizuno S, Sukegawa T, Inagaki T, Horiguo Seno H. et al .
Proton magnetic resonance spectroscopy (1 H MRS) of hippocampus, basal ganglia, and vermis of cerebellum in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert’s syndrome).
J Psychiatr Res.
2005;
39
29-34
28
Lindquist DM Hawk R M, Karson C R, Komoroski R A.
Effects of Antipsychotic Drugs on Metabolite Ratios i Rat Brain in Vivo.
Magn Reson Med.
2000;
43
355-358
29
Pae C U, Choe B Y, Joo R H, Lim H K, Kim T S, Too S S.
Neuronal dysfunction of the frontal lobe in schizophrenia.
Neuropsychobiology.
2004;
50
211-215
30
Sigmundsson T, Maier M, Toone B K, Williams S CR, Simmons A, Greenwood K. et al .
Frontal lobe N-acetyaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study.
Schizophr Res.
2003;
64
63-71
31
Stanley J A, Williamson P C, Drost D J, Rylett R J, Carr T J, Malla A. et al .
An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients.
Schizophr Bull.
1996;
22
597-609
32
Stanley J A.
Magnetic Resonance Spectroscopy in Schizophrenia: Methodological Issues and Findings-Part I.
Biol Psychiatry.
2000;
48
357-368
33
Tebartz van Elst L, Baumer D, Ebert D, Trimble M R.
Chronic Antidopaminergic Medication Might Affect Amygdala Structure in Patients with Schizophrenia.
Pharmacopsychiatry.
2004;
37
217-220
34
Théberge J, Al-Semaan Y, Williamson P C, Menon R S, Neufeld R W, Rajakumar N. et al .
Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.
Am J Psychiatry.
2003;
160
2231-2233
35
Théberge J, Bartha R, Drost D J, Menon R S, Malla A, Takhar J. et al .
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers.
Am J Psychiatry.
2002;
159
1944-1946
Dr. Agata Szulc
Department of Psychiatry
Medical University in Bialystok
16-070 Choroszcz, Pl. Brodowicza 1
Poland
Phone: +48 85 7193979
Fax: +48 85 7193978
Email: agataszulc@poczta.onet.pl